What is the clinical evidence from this study?

Study design: Observational. Population: Coronary artery disease and hypertension (n=142). Intervention: Benidipine vs. Nifedipine. Primary outcome: Major adverse cardiovascular events (MACE) (HR 0.28, 95% CI 0.08-1.00, p=0.049).

What does this research mean for the field?

Benidipine significantly reduces the risk of major adverse cardiovascular events compared to nifedipine in hypertensive patients with coronary artery disease, particularly in those with complicating chronic kidney disease. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the impact of long-acting calcium channel blockers on prognosis in patients with coronary artery disease and chronic kidney disease.

April 1, 2026Open Access

Impact of long-acting calcium channel blockers on the prognosis of patients with coronary artery disease with and without chronic kidney disease: A comparison of three drugs

Resultado clave

Benidipine significantly reduced the risk of major adverse cardiovascular events (HR 0.28) compared to nifedipine in hypertensive patients with coronary artery disease.

Puntos clave

To evaluate the impact of long-acting calcium channel blockers on prognosis in patients with coronary artery disease and chronic kidney disease.
Retrospective analysis of hypertensive patients with coronary artery disease who underwent coronary angiography.
Examined patients treated with benidipine, amlodipine, or long-acting nifedipine upon discharge.
Followed up for a mean of 5.2 years to assess major adverse cardiovascular events.
Significant reduction in systolic and diastolic blood pressure post-treatment.
Major adverse cardiovascular events occurred in 15 patients.
Chronic kidney disease significantly increased the risk of major adverse cardiovascular events (HR 2.35).
Benidipine demonstrated superior efficacy in preventing major adverse cardiovascular events compared to nifedipine.

Diseño del estudio

Tipo

Observational (n=142)

Multicéntrico

PICO estructurado

Does benidipine or amlodipine reduce MACE compared to nifedipine in hypertensive patients with CAD?

Población

Hypertensive patients with coronary artery disease (CAD) who had undergone a coronary angiograph

Intervención

Benidipine (mean 6.7 mg/day) or amlodipine (mean 5.1 mg/day)

Comparador

Long-acting nifedipine (mean 40.6 mg/day)

Resultado

Major adverse cardiovascular events (MACE) consisting of cardiac death, fatal or non-fatal myocardial infarction, or unstable angina pectoris requiring hospitalizationcomposite

In hypertensive patients with CAD, long-acting calcium channel blockers benidipine and amlodipine significantly reduced the frequency of MACE compared to nifedipine, particularly in those with concurrent chronic kidney disease.

Resultado numérico

Estimación del efecto: HR 0.28 (95% CI 0.08-1.00)

Tasa de eventos absoluta: 4.5% vs 22.6%

valor p: p=0.049

Limitaciones

Retrospective study design
Low number of patients treated with drug-eluting stents

Resumen

Calcium channel blockers (CCBs) can prevent cardiovascular events in patients with coronary artery disease (CAD). This study looked retrospectively at the prognosis of CAD in hypertensive patients with CAD who had undergone a coronary angiograph, had been given a CCB (benidipine n = 66, amlodipine n = 45, or long-acting nifedipine n = 31) on hospital discharge and were then followed up for a mean ± SD of 5.2 ± 2.9 years. Systolic/diastolic blood pressure for all 142 patients decreased significantly from a mean ± SD of 137 ± 20/74 ± 15 mmHg to 129 ± 20/71 ± 12 mmHg. Major adverse cardiovascular events (MACE) occurred in 15 patients. Chronic kidney disease (CKD) was a significant risk factor for MACE (hazard ratio 2.35, 95%confidence intervals 1.45, 3.80). Benidipine was superior to nifedipine in preventing MACE in patients both with and without CKD. In conclusion, benidipine and amlodipine reduced the frequency of MACE in hypertensive patients with CAD, particularly in those with complicating CKD. © 2010 Field House Publishing LLP.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo